Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible

被引：0

作者：

Su, Yi-Jiun ^{[1
,2
]}

Kramer, Anne Marijn ^{[3
,4
]}

Hamilton, Mark P. ^{[2
,4
]}

Agarwal, Neha ^{[2
,4
]}

Feldman, Steven ^{[4
]}

Sahaf, Bita ^{[4
,5
]}

Kuo, Adam ^{[4
,5
]}

Mackall, Crystal L. ^{[2
,4
,6
]}

Muffly, Lori S. ^{[2
,4
]}

Miklos, David B. ^{[4
,7
]}

Frank, Matthew J. ^{[4
,7
]}

机构：

[1] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Taoyuan, Taiwan

[2] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Palo Alto, CA USA

[3] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Menlo Pk, CA USA

[4] Stanford Univ, Stanford Canc Inst, Ctr Canc Cell Therapy, Stanford, CA USA

[5] Stanford Univ, Canc Correlat Sci Unit, Palo Alto, CA USA

[6] Stanford Univ, Div Hematol Oncol, Dept Pediat, Sch Med, Stanford, CA USA

[7] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Palo Alto, CA USA

来源：

关键词：

D O I：

10.1182/blood-2023-185413

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4